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Abstract 
Background: Cost-effectiveness analyses provide insight in the use of lifestyle interventions. To evaluate the cost-
effectiveness of a lifestyle intervention compared to usual care in people with Familial Hypercholesterolemia, 340 
people with FH were randomized to the intervention or control group. LDL cholesterol, quality of life and costs were 
measured at 0 and 12 months. Cost-effectiveness analyses were performed from a healthcare perspective using boot-
strapping techniques.
Results: Non-significant decreases in LDL cholesterol and quality of life were found. The mean between-group differ-
ence in costs was €−237 (95% CI −1,386 to 130). The incremental cost-effectiveness ratios were 1,729 per 1 mmol/l 
LDL cholesterol and 145,899 per QALY gained. Assumed that the small non-significant decrease in LDL cholesterol is 
attributed to the intervention, the probability of cost-effectiveness of the intervention compared to usual care was 
91% per 1 mmol/l LDL cholesterol reduction and 75% per QALY gained at a ceiling ratio of €20,000.
Conclusions: The intervention is not cost-effective.
Trial registration: NTR1899, date 07-07-2009.
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Background
In the Netherlands, approximately one in every 500 peo-
ple is affected with Familial Hypercholesterolemia (FH) 
[1], which is a genetic disorder of the lipoprotein metabo-
lism, associated with elevated plasma concentrations of 
LDL-C [2]. Elevated serum LDL-C and FH are associ-
ated with an increased risk of early cardiovascular disease 
(CVD) [3]. Since 1994, already 23,668 of the estimated 
40,000 mutation carriers have been found and genetically 
diagnosed through the cascade screening program of the 
Dutch Foundation for Tracing Hereditary Hypercholes-
terolemia (in Dutch: StOEH) [4].
CVD is a major contributor to the global burden of dis-
ease, as it decreases quality of life and accounts for 20% 
of disability-adjusted life years (DALYs) lost in developed 
countries [5]. CVD also constitutes a large economic bur-
den, as approximately 10% of the European health budget 
is spent on CVD [6]. Moreover, productivity losses due to 
premature death and illness of CVD patients of working 
age and costs due to informal care for people with CVD 
also contribute greatly to the societal economic burden 
(21% of the total costs of CVD) [6]. Results of primary 
prevention trials in high-risk persons and secondary 
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prevention trials in CVD patients show that substantial 
reductions in CVD risk can be achieved through lifestyle 
changes [7–9]. Given the burden of CVD and the lim-
ited resources available for health care, information on 
the cost-effectiveness of available intervention strategies 
to reduce CVD risk is important. The aim of this study 
is to assess the cost-effectiveness and the cost-utility of 
an individually tailored lifestyle intervention compared 




An economic evaluation was conducted from a health-
care perspective alongside a randomized controlled trial 
(RCT). Details on the design of the project and the inter-
vention content have been published elsewhere [10]. 
The study design and informed consent procedure were 
approved by the Medical Ethics Committee of the VU 
University Medical Center and all participants provided 
written informed consent. The trial has been registered at 
dutchtrialregister.nl as NTR1899.
Study population and setting
Participants diagnosed with the heterozygous type 
of FH from January 1st 2007 to April 15th 2009, aged 
18–70  years and with a LDL-C level >75th percen-
tile (age and gender specific) were recruited from the 
national cascade screening program of the StOEH [4]. 
Access to internet, sufficient fluency in Dutch and resi-
dency <150 km radius from Amsterdam were additional 
eligibility criteria. Conservatively, it was expected that 
the primary outcome LDL-C could be lowered by 35%. 
With an alpha of 0.05, 200 participants in the inter-
vention and 200 in the control group and an expected 
drop-out of 20%, power to statistically detect an inter-
vention effect of 9% was 90%. Participants were ran-
domly assigned to either the control group (n =  159) 
or the intervention group (n  =  181) through a strati-
fied computerized blinded randomisation procedure 
using Microsoft© Office Access 2003 software. Partici-
pants were stratified according to cholesterol lowering 
medication use (yes/no), assuming that medication use 
implicates treatment by a general practitioner and/or 
medical specialist, who could have already given advice 
on lifestyle behavior. In addition, we expected that the 
potential decrease in LDL-C because of the interven-
tion would be smaller if a participant already used 
medication. Family members from the same house-
hold were clustered and subsequently randomized as 
a cluster to prevent contamination due to spill over of 
communication about the intervention among family 
members.
Intervention and control
The intervention consisted of a combination of tailored 
web-based advice (PRO-FIT*advice) and one face-to-
face counselling session complemented with telephone 
booster sessions (PRO-FIT*coach) [10]. The goal of the 
intervention was to improve awareness of the CVD risk, 
by increasing knowledge about CVD risk based on cur-
rent lifestyle behavior, cues to action and change in risk 
perception, and to lower LDL-C levels and adopt and 
maintain a healthier lifestyle, regarding physical activity, 
saturated fat intake, fruit and vegetables intake, smoking 
and compliance to statin therapy [10].
Briefly, participants were encouraged to visit a web 
link referring to the project website, where generic CVD 
risk information was presented, containing information 
on CVD risk behaviors and their contribution to overall 
CVD risk, as well as information on the changeability 
of these behaviors and cues on how to change behav-
iors. Thereafter, participants could log on to a personal 
PRO-FIT*advice account, consisting of six advice mod-
ules on smoking, physical activity, saturated fat intake, 
fruit intake, vegetables intake and compliance to statin 
therapy. On-screen personalized feedback was tailored 
to personal performance level (current lifestyle behavior), 
awareness of one’s own performance, as well as personal 
motivation to change, outcome expectations, attitude 
and self-efficacy.
Subsequently, one face-to-face counselling session 
was provided to each participant by a lifestyle coach at 
the participants’ home with a duration of 45  min. The 
assessment(s) and advice(s) within the participant’s 
personal PRO-FIT*advice account were discussed, and 
ambivalence and barriers related to the recommended 
behavior changes were explored using Motivational 
Interviewing (MI) techniques [11]. In the following 
9 months, the lifestyle coach offered one to five booster 
telephone sessions of 15 min per participant, to encour-
age the participant’s behavioral changes and to provide 
further brief MI to encourage the planned behavioral 
changes.
The control group received care as usual, which means 
that they received no extra intervention besides the care 
they already received: at least one visit to the general 
practitioner and/or medical specialist a year and the use 




LDL-C was measured at baseline and 12  months with 
fasting finger stick samples analysed on a Cholestech 
LDX desktop analyser (Cholestech, Hayward, USA) 
[10]. For the cost-utility analysis, the EuroQol-5D 
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(EQ-5D) was used to assess quality of life at baseline and 
at 12 months [12]. To estimate the utility of health states 
described by the participants, the Dutch tariff was used 
[13]. Quality adjusted life years (QALYs) were calculated 
by multiplying the utilities with the amount of time a 
participant spent in a particular health state. Transitions 
between health states were linearly interpolated.
Cost measures
Data were collected from a healthcare perspective, i.e. 
only healthcare-related costs were included in the eco-
nomic evaluation. Prices were adjusted for the year 2010, 
the year in which most data were collected, using con-
sumer price indices [14].
Information on healthcare utilization and prescribed 
medication associated with FH and/or CVD was 
obtained through a 12-month retrospective question-
naire. Healthcare utilization consisted of costs of primary 
care (including general practitioner and therapist care) 
and secondary care (including medical specialist care and 
hospitalization associated with FH and/or CVD), and 
were valued with Dutch standard costs [15]. If these were 
not available, prices according to professional organiza-
tions were used. The costs of prescribed medication were 
calculated using prices charged by the Royal Dutch Soci-
ety for Pharmacy [16].
Intervention costs were estimated using a bottom-
up micro-costing approach, i.e. detailed data were col-
lected regarding the quantity of resources consumed per 
patient as well as their unit prices. Costing was based on 
the assumption that the intervention would be imple-
mented for a 5-year period by an academic medical 
center. According to StOEH data, approximately 2,700 
people would be eligible and willing to participate during 
this period [4]. Consequently, five lifestyle coaches would 
be needed for the coaching component of the interven-
tion. Variable costs per participant depended on the 
number of counselling sessions received and were cal-
culated using annual salaries of the lifestyle coaches with 
added taxes and benefits. Intervention costs addition-
ally included costs of the development and implementa-
tion of materials, training and supervision of the lifestyle 
coaches, and the development and implementation of the 
PRO-FIT*advice web-environment.
Statistical analyses
Missing healthcare costs, QALY data and LDL-C levels 
were multiply imputed in SPSS 17 creating ten different 
data sets [17–19]. Data were imputed separately for the 
intervention and control group. The imputational model 
included important demographics and prognostic variables 
associated with the missing data: age, gender, LDL-C lev-
els and body mass index (BMI) at baseline and follow-up, 
intervention costs, primary care (general practitioner and 
therapist) costs, secondary care (outpatient visits and hos-
pital admission) costs and medication costs, and utilities 
at baseline and follow-up. Pooled estimates of effects and 
costs were estimated according to Rubin’s rules [20].
Main analyses were according to the intention to treat 
principle and based on the imputed data. Differences in 
baseline characteristics between the intervention and con-
trol group and between cases with missing data and cases 
with complete data were tested using linear and logistic 
regression analysis. The effects on clinical outcomes at 
12 months were analysed using linear regression analyses, 
adjusted for baseline values. Mean cost differences between 
the intervention and control group were calculated for pri-
mary and secondary care, medication, and total costs. The 
Approximate Bootstrap Confidence algorithm with 5,000 
bootstrap samples was used to estimate 95% confidence 
intervals surrounding the cost differences [21]. Incremental 
cost-effectiveness ratios (ICERs) were calculated by divid-
ing the difference in total costs between the intervention 
and control group by the difference in clinical outcomes 
adjusted for baseline values. The ICER indicates the addi-
tional investments needed for the intervention group to 
gain one extra unit in health effect, i.e. 1 mmol/l LDL-C and 
1 QALY, in comparison with usual care. The bootstrapped 
cost–effect pairs were graphically presented in a cost-effec-
tiveness plane, to show the uncertainty around the ICER. 
Cost-effectiveness acceptability curves (CEACs) were also 
estimated. CEACs show the ‘willingness to pay’ for a unit 
of health effect extra (i.e. ceiling ratio) on the x-axis and 
the corresponding probability that the intervention is cost-
effective at that ceiling ratio on the y-axis. All analyses were 
done in R (version 2.10.1) [22].
To assess the robustness of the results, three sensitivity 
analyses were performed. First, a cost-effectiveness anal-
ysis (CEA) taking only complete cases into account was 
conducted (CEA2). Second, a CEA was performed using 
the actual costs of the PRO-FIT intervention within the 
PRO-FIT trial (including 340 participants, two lifestyle 
coaches, implemented in a 1-year period) (CEA3). Third, 
a CEA was conducted in which the hospital admission 
costs were excluded from the total costs (CEA4).
Results
Participant flow and baseline characteristics
Invitation letters were sent to 986 people, of whom 340 
(34%) responded and participated in the trial. The par-
ticipant flow is presented in Fig.  1. A small proportion 
of participants decided to discontinue participation or 
was lost to follow-up in both the intervention (5%) and 
control group (8%), resulting in 318 participants com-
pleting the study. The number of participants with com-
plete follow-up data ranged from 64 to 90%. Baseline 
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characteristics are given in Table  1. A significant dif-
ference in baseline BMI between intervention and con-
trol group was found (mean difference  =  −1.10; 95% 
CI: −2.16 to −0.05) in the imputed and complete cases 
dataset. As a consequence, baseline BMI values were 
included in all analyses of cost-effectiveness regarding 
LDL-C and QALYs.
Intervention compliance
Of the 181 participants in the intervention group, 95% 
received a PRO-FIT*advice log on account. The remain-
ing 5% (9 participants) explicitly reported to have no 
interest in using PRO-FIT*advice and therefore, received 
no log on information. Subsequently, 49% of remain-
ing 172 participants actually logged on and completed 
Fig. 1 Flow of participants in the PRO-FIT project. Figure 1 shows the flow of participants from recruitment to analysis in the PRO-FIT project, con-
ducted in 2009–2010 in the Netherlands among 340 adults with Familial Hypercholesterolemia.
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at least one out of six advice modules. Nearly all partici-
pants (99%) received the face-to-face counselling session 
and on average, 4.2 telephone booster calls were con-
ducted with 181 participants.
Clinical outcomes
After 12  months, LDL-C had decreased in both groups 
and by 0.14 mmol/l more in the intervention group. The 
intervention group had 0.002 QALYs less than the con-
trol group. These between-group differences for LDL-C 
and QALYs were small and statistically non-significant 
(see Table 2).
Costs
Intervention costs are presented in Table  3 and mainly 
consisted of the costs of counselling (91%). Pooled mean 
costs and cost differences between the intervention and 
control group are presented in Table 4. Around one-third 
of total costs in both groups consisted of medication 
costs. Primary care costs were statistically significantly 
lower in the intervention group in comparison with the 
control group. Secondary care costs in the control group 
were considerably higher than in the intervention group 
due to one extended hospitalization in this group. How-
ever, the difference in secondary costs was not statisti-
cally significant. Overall healthcare-related costs were 
€237 lower in the intervention group but this difference 
was not statistically significant (−1,386 to 130).
Cost‑effectiveness
Assuming that the non-significant difference in LDL-C 
between intervention and control group can be attrib-
uted to the intervention, the main analysis showed that 
the pooled ICER for LDL-C was €1,729 (see Table  5), 
indicating that a 1 mmol/l decrease in LDL-C concentra-
tion extra as a result of the PRO-FIT intervention saves 
€1,729, compared to usual care. The cost-effectiveness 
plane for LDL-C (Fig. 2a) showed that 68% of the boot-
strapped cost-effectiveness pairs were located in the 
southeast quadrant, the quadrant in which the inter-
vention is dominant over usual care. The CEAC curve 
(Fig. 2b) showed that if a decision maker is willing to pay 
€4,000 for 1  mmol/l LDL-C reduction, the probability 
that the PRO-FIT intervention is cost-effective is 93%, 
but thereafter reduces to a maximum of 91%.
Cost‑utility
The ICER of €145,899 per QALY indicates that 1 QALY 
lost as a result of the PRO-FIT intervention saves the 
healthcare sector €145,899, compared to usual care (see 
Table 5).
In the cost-effectiveness plane (Fig. 3a), most cost-util-
ity pairs (44%) were located in the southwest quadrant, 
the quadrant in which less QALYs are gained at lower 
costs in the intervention group compared with usual 
care. The CEAC (Fig.  3b) indicated that the probability 
of cost-utility of the PRO-FIT intervention compared to 
usual care ranged from approximately 75% at a ceiling 
ratio of €0 per QALY gained to 55% at a ceiling ratio of 
€120,000 per QALY gained.
Sensitivity analyses
Results of the sensitivity analyses based on complete 
cases (CEA2) and based on the actual intervention costs 
of the PRO-FIT intervention (CEA3) were similar to the 
results from the main analyses (see Table  5). The CEA 
that excluded hospital admission costs led to smaller cost 
differences and costs were lower in the control group.
Discussion and conclusions
The results of this study show that the PRO-FIT inter-
vention was not cost-effective in comparison with 
Table 1 Baseline characteristics of  people with  Familial 
Hypercholesterolemia in  control and  intervention group 
after multiple imputation
Significant differences between control and intervention group (P < 0.05) are 
printed in italics font.
a Assessed by the EuroQol-5D; N sample size, SD standard deviation, BMI body 





Gender, N (% female) 90 (57) 104 (57)
Mean age in years (SEM) 46.0 (1.0) 44.7 (1.0)
Mean BMI in kg/m2 (SEM) 27.1 (0.4) 26.0 (0.3)
Statin use, N (% yes) 110 (69) 123 (68)
EQ-5D utility score (SEM)a 0.9 (0.01) 0.9 (0.01)
Table 2 Pooled intervention effects on LDL-C and QALYs after 12 months
Effects were calculated after multiple imputation and with adjustment for baseline values.
LDL-C low-density lipoprotein cholesterol, QALY quality adjusted life year, SEM standard error of the mean; the maximum QALY that can be achieved in one year is 1 
unit.
Pooled effects (pooled mean (SEM)) Control group N = 159 Intervention group N = 181 Intervention versus control
Baseline Follow‑up Baseline Follow‑up Mean difference (95% CI)
LDL-C (mmol/l) 3.7 (0.1) 3.6 (0.1) 3.7 (0.1) 3.5 (0.1) −0.14 (−0.34 to 0.07)
QALYs achieved – 0.9 (0.01) – 0.9 (0.01) −0.002 (−0.02 to 0.01)
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usual care. No statistically significant differences were 
found in LDL-C, QALYs and health care costs after 
12 months. Our study is the first to evaluate the cost-
effectiveness of a lifestyle intervention compared to 
usual care in a FH sample. Other studies concluded 
that lifestyle interventions are cost-effective in reduc-
ing the long-term risk of type 2 diabetes and CVD [23]. 
However, our findings show no value in the addition 
of lifestyle advice to treatment with statins, which has 
already been shown to be cost-effective in people with 
FH [24].
All further discussion and interpretation of the present 
results regarding cost-effectiveness should obviously be 
regarded with caution, since we cannot conclude that the 
non-significant decrease in LDL-C and related gain in 
QALYs were coincidental or caused by the intervention. 
For the sake of this economic evaluation, the found dif-
ferences compared to the usual care were regarded as real 
Table 4 Pooled mean differences in healthcare-related costs per participant in Euros between baseline and 12-months 
follow-up
SEM standard error of the mean, NA not available; costs are given in 2010 Euros; mean differences were calculated after multiple imputations.
a Prescribed statins.
Pooled costs [pooled mean (SEM)] Control group Intervention group Mean cost difference (%CI)
PRO-FIT intervention 0 163 163 (NA)
Primary care 86 (17) 44 (8) −43 (−86 to −11)
Secondary care 461 (289) 121 (51) −340 (−1,406 to 24)
Medicationa 284 (29) 266 (23) −17 (−91 to 54)
Total costs 831 (297) 594 (60) −237 (−1,386 to 130)
Table 3 Overview of costs of the PRO-FIT intervention in Euros per participant
hrs hours, mins minutes.
a Salary costs were derived from the Collective Labour Agreement for Dutch Academic Medical Centers (CAO UMC) 2010 (for junior researcher, lifestyle coach and 
supervisor), or by price offers from web developers, graphic/brochure designers.
§ Costing was based on invoices/price offers.
Cost category Included resources Cost prices per unita Costs per participant
Development
 Developmental costs of brochure  
and coaching logs
Content development (30 h) by junior researcher
Concept development/graphic design (24 h) by 
graphic designer





 Computer-based part of intervention,  
including website and application  
for providing computer-tailored advice
Web development (12 h) by web-developer
Registration website (once)
Development/adjustment tailoring application by 







 Brochures, logs, website and tailoring  
application







Implementation based on 2,700 participants and an implementation period of 5 years
 Training of lifestyle coaches A 3-day Motivational Interviewing workshop
5 lifestyle coaches, 3 days, 8 h/day





 Supervision of lifestyle coaches  
(10 meetings of 2 h each)







 Counselling 1 face-to-face counselling session (45 min) by 
lifestyle coach
5 telephone booster sessions (15 min/session) by 
lifestyle coach
Administrative work (25 min/participant) by lifestyle 
coach







Total intervention costs Є 163.13
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and attributable to the intervention. Having conducted a 
CEA for an intervention for which no evidence of effect 
was found as compared to usual care seems to have limited 
value. Though, conducting CEAs while significant effects 
are lacking is of great importance, e.g. for systematic 
reviews on the cost-effectiveness of interventions. These 
reviews are often hampered by a publication bias, since 
CEAs are generally only conducted if an intervention was 
significantly effective and are therefore overrepresented 
[25, 26]. Further, this study examines the joint distribution 
of costs and effects. This is relevant because even if costs 
and effects show no significant differences, the joint dis-
tribution could indicate that a treatment is cost-effective 
in comparison with control for some ceiling ratios [27]. In 
addition to the economic evaluation, the transparent over-
sight of the intervention costs and healthcare-related costs 
that we provided is relevant for policy-makers and future 
researchers planning a similar RCT.
Intervention costs were computed as if the interven-
tion was implemented with full compliance. Taking into 
account the actual compliance during the trial would not 
lead to a substantial difference in intervention costs, as 
Table 5 Results for cost-effectiveness and cost-utility analyses
Sample size Cost difference in Euros 
(95% CI)
Effect difference (95% 
CI)
ICER Distribution cost‑effectivess 
plane (%NE/SE/SW/NW)
I C
Main analysis (CEA1) 181 159 LDL-C −237 (−1,386 to 130) −0.14 (−0.34 to 0.07) 1,729 22.5/68.5/7.1/1.9
181 159 QALY −237 (−1,386 to 130) −0.002 (−0.02 to 0.01) 145,899 9.7/30.9/44.2/15.2
Complete case analysis 
(CEA2)
118 100 LDL-C −364 (−2,030 to 238) −0.14 (−0.37 to 0.08) 2,012 4.6/8.0/55.7/31.7
157 136 QALY −301 (−1,680 to 109) −0.003 (−0.03 to 0.03) 100,347 6.5/25.4/52.5/15.6
Intervention costs as in RCT 
(CEA3)
181 159 LDL-C −88 (−1,248 to 277) −0.14 (−0.34 to 0.07) 645 39.4/51.6/5.5/3.6
181 159 QALY −88 (−1,248 to 277) −0.002 (−0.02 to 0.01) 54,426 17.1/23.4/33.8/25.7
Hospital admission costs 
excluded (CEA4)
181 159 LDL-C 94 (−6 to 193) −0.14 (−0.34 to 0.07) −690 88.5/2.4/0.5/8.5
181 159 QALY 94 (−6 to 193) −0.002 (−0.02 to 0.01) −33,676 38.9/1.2/1.7/58.2
Fig. 2 a and 2b: Pooled cost-effectiveness plane and cost-effectiveness acceptability curve for the difference in LDL-C after 12 months. Figure 2a 
and 2b show the pooled cost-effectiveness plane and cost-effectiveness acceptability curve for the difference in LDL-C after 12 months within the 
PRO-FIT project, conducted in 2009–2010 in the Netherlands among 340 adults with Familial Hypercholesterolemia.
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the proportion of participants that received face-to-face 
counselling was 99%. However, the intervention costs 
in this study were based on five telephone booster calls, 
whereas on average 4.2 were conducted during the trial. 
Consequently, the actual intervention costs are only 
slightly less (€155.46 instead of €163.13).
Secondary care costs in the control group were consid-
erably higher than in the intervention group and this con-
tributed most to the difference in total healthcare-related 
costs between the groups. Further analysis showed that 
this was caused by higher mean hospital admission costs 
associated with FH and/or CVD in the control group 
than in the intervention group. A sensitivity analysis 
excluding hospital admission costs showed that, in con-
trast to the main CEA analysis, costs in the intervention 
group were higher than in the control group, but this dif-
ference was not statistically significant and the interven-
tion was still not considered cost-effective.
Limitations of this economic evaluation should be taken 
into consideration. At first, the evaluation was performed 
from a healthcare perspective, while Dutch guidelines 
recommend adapting a societal perspective. We chose 
this perspective since our central aim was to lower LDL-C 
with lifestyle changes, and no effects on productivity 
costs due to the intervention in the follow-up period were 
expected. Second, information on healthcare utilization 
and prescribed medication was obtained through a 
12-month retrospective questionnaire. Shorter recall 
periods reduce the chance of recall bias, though more fre-
quent measurements with a shorter recall period could 
have increased the chance of missing data, compared with 
one measurement with a recall period of 12 months [28]. 
Third, whereas intervention costs were complete, data on 
healthcare-related resource use and LDL-C/QALYs were 
missing for 36 and 14% of the participants, respectively. 
To account for these missing data, multiple imputation 
techniques were used. Multiple imputation is preferred 
over complete case analysis [28], since a complete-case 
analysis is inefficient, as the sample size is smaller and it 
ignores observed cost and/or effect data in the excluded 
participants. The advantage of using multiple imputation 
is that the uncertainty associated with imputing missing 
values is also taken into account in the pooled estimates. 
Overall, it is likely that the effect of lifestyle improvements 
is likely to lead to CVD risk reduction at the longer term 
(>12  months). Inclusion of more long-term follow-up 
measurements would clarify intervention effects on CVD 
risk and hard outcomes (e.g. CVD/death) and would allow 
a more thorough cost-effectiveness analysis.
In conclusion, an individually tailored lifestyle inter-
vention in people with FH was not cost-effective com-
pared to usual care. Due to the non-significant small 
Fig. 3 a and 3b: Pooled cost-effectiveness plane and cost-effectiveness acceptability curve for QALYs gained after 12 months. Figure 3a and 3b 
show the pooled cost-effectiveness plane and cost-effectiveness acceptability curve for the difference in QALYs after 12 months within the PRO-FIT 
project, conducted in 2009–2010 in the Netherlands among 340 adults with Familial Hypercholesterolemia.
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effects found in the study, the conclusions should be 
regarded with caution.
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